Bizekis Costas, Kent Michael S, Luketich James D, Buenaventura Percival O, Landreneau Rodney J, Schuchert Matthew J, Alvelo-Rivera Miguel
Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA.
Ann Thorac Surg. 2006 Aug;82(2):402-6; discussion 406-7. doi: 10.1016/j.athoracsur.2006.02.052.
We have previously reported our experience with minimally invasive esophagectomy. Our standard approach involves laparoscopic and thoracoscopic mobilization of the esophagus with a cervical esophagogastric anastomosis. In the present study we report our early experience with a modification of this technique, in which a high intrathoracic anastomosis is performed.
From 2002 to 2005, a minimally invasive Ivor Lewis esophagectomy was performed in 50 patients. The planned approach included a totally laparoscopic abdominal procedure and either a minithoracotomy or thoracoscopy. Indications for esophagectomy included short segment Barrett's esophagus with high-grade dysplasia or resectable adenocarcinoma of the gastroesophageal junction (GEJ) with minimal proximal esophageal extension. .
The median age was 62.3 years (range, 38 to 79). Twenty-five patients (50%) received either preoperative chemotherapy or chemoradiation. There was one nonemergent conversion to an open procedure during laparoscopy. Planned minithoracotomy was successful in 35 patients; an additional 15 patients had the entire thoracic component performed thoracoscopically. A circular stapled anastomosis was performed in all patients. The operative mortality was 6%. Three patients (6%) developed an anastomotic leak; all were successfully managed nonoperatively. Four patients (8%) developed postoperative pneumonia. There were no recurrent laryngeal nerve injuries.
Minimally invasive Ivor Lewis esophagectomy was technically feasible and resulted in good initial results in our center, which is experienced in minimally invasive and open esophagectomy. This approach minimizes the degree of gastric mobilization, almost eliminates recurrent laryngeal nerve injury and pharyngeal dysfunction, and allows additional gastric resection margin in the case of cardia extension of GEJ tumors.
我们之前报告了我们在微创食管切除术方面的经验。我们的标准方法包括通过腹腔镜和胸腔镜游离食管并进行颈部食管胃吻合术。在本研究中,我们报告了对该技术进行改良后的早期经验,即进行高位胸内吻合术。
2002年至2005年,对50例患者实施了微创艾弗·刘易斯食管切除术。计划采用的方法包括全腹腔镜腹部手术以及开胸小切口或胸腔镜手术。食管切除术的适应证包括短节段伴有高级别异型增生的巴雷特食管或胃食管交界(GEJ)处可切除的腺癌且食管近端受累最小。
中位年龄为62.3岁(范围38至79岁)。25例患者(50%)接受了术前化疗或放化疗。腹腔镜手术期间有1例非急诊转为开放手术。计划的开胸小切口手术在35例患者中成功实施;另外15例患者通过胸腔镜完成了整个胸部部分的手术。所有患者均进行了圆形吻合器吻合。手术死亡率为6%。3例患者(6%)发生吻合口漏;均通过非手术成功处理。4例患者(8%)发生术后肺炎。无喉返神经损伤。
微创艾弗·刘易斯食管切除术在技术上是可行的,并且在我们这个在微创和开放食管切除术方面经验丰富的中心取得了良好的初步结果。这种方法可将胃游离程度降至最低,几乎消除喉返神经损伤和咽部功能障碍,并且在GEJ肿瘤累及贲门时可提供额外的胃切除切缘。